Beyond Semaglutide: The Next Wave of GLP-1 Drugs Targets the Heart, Kidneys, and Joints

The short version: a wave of new papers suggests these drugs behave less like a single-purpose appetite tool and more like a multi-organ protective therapy. A 2025 review in Peptides lays out the case directly, describing incretin-based medicines as agents that lower glucose and weight, yes, but also confer benefits against cardiovascular and renal disease that go beyond what those two changes alone would predict — with emerging signals for fatty liver disease, chronic inflammation, sleep apnea, and possibly bone and cognitive health. The authors also catalogue a growing pharmacy of next-generation molecules — dual and triple agonists, peptide-antibody hybrids, oral versions — that are pushing the category well past semaglutide and tirzepatide. You can read the full taxonomy in the review itself.

That is the optimistic frame. Now the honest one: most of this is moderate-strength evidence. Some of it is preclinical. Some is retrospective. None of it justifies treating a GLP-1 like a cure-all, and none of it should be acted on without a clinician who actually knows your chart.

Cardiac remodeling — the gradual thickening and scarring of heart muscle under chronic strain — is the kind of slow-motion problem that ends careers in cardiology. So it was notable when a 2025 paper in the Journal of Cellular and Molecular Medicine reported that danuglipron, a novel oral GLP-1 receptor agonist, meaningfully reduced pressure-overload-induced hypertrophy and fibrosis in mice. The mechanism is the interesting part: the drug appears to work through AMPK phosphorylation and a bump in HSP70, easing apoptosis and supporting autophagy. When the researchers knocked out AMPKα2, the cardioprotection vanished — strong evidence the pathway is real, not coincidence. The full study is here.

Caveat the size of a barn: this is a mouse model. Danuglipron is not approved, and oral GLP-1 development has had a bumpy road. What this paper offers is a plausible biological story for why GLP-1 receptor activation might do something useful for stressed hearts — a hypothesis worth chasing, not a prescription.

This is where the evidence gets sturdier — and more personally relevant for anyone navigating diabetes and weight in midlife. A retrospective cohort study published in The Lancet Diabetes & Endocrinology in 2025 looked at U.S. kidney transplant recipients with type 2 diabetes — a group routinely excluded from the big GLP-1 trials because they are too complicated: longer diabetes duration, more end-organ damage, more cardiovascular risk, more medications. Using a national registry linked to Medicare claims, the researchers identified more than 44,000 first-time kidney transplant recipients and examined what happened when post-transplant patients started a GLP-1 receptor agonist. Their framing is cautious but the question is exactly the right one: do the benefits seen in healthier trial populations carry over to the patients who arguably need them most? The full paper is the place to dig in.

Dialysis patients have been similarly invisible in pivotal trials. A 2025 letter in Cardiovascular Diabetology highlights that the 2022 KDIGO guideline already endorses GLP-1 receptor agonists for patients with chronic kidney disease and type 2 diabetes who have not hit glycemic targets on metformin and an SGLT-2 inhibitor — and signals potential benefit even in dialysis-requiring acute kidney disease, possibly via the drug class's pleiotropic effects. The authors are appropriately careful: pharmacokinetics and dialysis dose were not fully accounted for, and they flag this as a real limitation. Their commentary is worth reading in full. Translation for the rest of us: promising direction, incomplete map.

Here is the entry on the list that made every editor in our newsroom do a double take. A 2025 prospective cohort study in the Journal of Orthopaedic Surgery and Research followed more than 2,000 adults with chronic ankle instability — the chronic sprain-and-roll problem that haunts people who once played sports or who simply carry extra load on imperfect joints — across three medical centers for at least two years. Seventy-one of those patients received semaglutide during the study period, prescribed for diabetes or weight loss. After adjusting for baseline differences, the semaglutide group showed a 16.3-point improvement on the FAAM sports subscale and 9.3 points on the activities-of-daily-living subscale, with consistent gains across Foot and Ankle Outcome Score subscales and the Cumberland Ankle Instability Tool. The authors note the effect was mediated, at least in part, by weight loss. The full study is here.

Is this evidence that GLP-1s are a treatment for bad ankles? No. It is evidence that taking meaningful load off joints, in a population that was unstable to begin with, may translate into measurably better function and fewer sprains. Which, if you have ever rolled your ankle stepping off a curb at 47, is its own small revolution.

If you are a woman somewhere in the perimenopausal sprawl, weighing whether a GLP-1 belongs in your life, the new research does not hand you an answer. It does change the shape of the conversation. The question is no longer just "will this help me lose weight?" It is also "what else might this be doing — for better, and worth monitoring — in a body that is also juggling shifting hormones, blood pressure, cholesterol, and joints that have opinions?" That is a conversation for an actual clinician with your labs in front of them, not for a magazine. But it is a more interesting conversation than it was a year ago.

The hype cycle will keep doing what hype cycles do. The science, meanwhile, is getting more careful, more curious, and — refreshingly — more honest about who has been left out of the trials. That is the part to watch.